All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C326 | Human anti-Alfa gliadin T cell receptor (CB-C066), pCDTCR1 | Einkorn wheat | CB-C066 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C327 | Human anti-Alfa gliadin T cell receptor (CB-C067), pCDTCR1 | Einkorn wheat | CB-C067 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C328 | Human anti-Alfa gliadin T cell receptor (CB-C068), pCDTCR1 | Einkorn wheat | CB-C068 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C329 | Human anti-Alfa gliadin T cell receptor (CB-C069), pCDTCR1 | Einkorn wheat | CB-C069 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C330 | Human anti-Alfa gliadin T cell receptor (CB-C070), pCDTCR1 | Einkorn wheat | CB-C070 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C331 | Human anti-Alfa gliadin T cell receptor (CB-C071), pCDTCR1 | Einkorn wheat | CB-C071 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C332 | Human anti-Alfa gliadin T cell receptor (CB-C072), pCDTCR1 | Einkorn wheat | CB-C072 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C333 | Human anti-Alfa gliadin T cell receptor (CB-C073), pCDTCR1 | Einkorn wheat | CB-C073 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C334 | Human anti-Alfa gliadin T cell receptor (CB-C074), pCDTCR1 | Einkorn wheat | CB-C074 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector | |
TCR-C335 | Human anti-Alfa gliadin T cell receptor (CB-C075), pCDTCR1 | Einkorn wheat | CB-C075 | Human | PQPELPYPQPE | HLA-DQ2 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION